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INTRODUCTION
Acute graft-versus-host disease (GVHD) is a major cause
of morbidity and mortality after hematopoietic stem cell
transplantation (HSCT). Whereas HLA disparity between
donor and recipient is a major GVHD risk factor, bacteria
have long been postulated to contribute to the pathogenesis
of GVHD [1,2]. A protective environment was found to
decrease the incidence of GVHD after marrow transplanta-
tion in aplastic anemia patients [3], whereas higher-dose total
body irradiation regimens that damage gut mucosa and facil-
itate translocation of bacteria and bacterial products
increased the incidence of GVHD [4]. Gram-negative bacte-
ria and their cell wall component, lipopolysaccharide (LPS),
have been implicated in experimental GVHD in murine
transplantation models [1]. GVHD in mice was less severe in
(C3FeB6)F1 recipients of bone marrow from LPS-resistant
(C3H/HeJ) donors compared with recipients of bone mar-
row from LPS-sensitive (C3HeB/FeJ) donors [5].
The toll-like receptor (TLR)-4 has recently been identi-
ﬁed as a signal-transducing component in the LPS receptor
complex. C3H/HeJ and C57BL/10ScCr mouse strains with
low responses to LPS have mutations in TLR4 [6]. The
missense mutation in C3H/HeJ mice is codominant in that
heterozygotes have intermediate responses to LPS. A TLR4
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ABSTRACT
Lipopolysaccharide (LPS) has been implicated in the pathogenesis of graft-versus-host disease (GVHD). The toll-
like receptor (TLR)-4 has been recently identified as a major receptor for LPS. Mutations of TLR4 have been asso-
ciated with LPS hyporesponsiveness. We hypothesized that TLR4 mutations reduce the risk of acute GVHD in
allogeneic marrow transplant recipients. In a preliminary study to determine the frequency of TLR4 mutations and
their possible association with GVHD, we tested 237 patients and their HLA-identical sibling donors for 2 TLR4
polymorphisms. All patients received methotrexate and cyclosporine for GVHD prophylaxis. One or more mutants
were detected in 10.8% of patients and 10.6% of donors. Multivariable logistic regression models were used to ana-
lyze the association between TLR4 mutations and probability (1-sided) of GVHD. The odds ratio (adjusted for
advanced disease, total body irradiation dose, and patient age) for development of grades II to IV GVHD when a
mutation was present in the recipient was 0.63 (95% confidence interval [CI], 0.25-1.60; P = .16). When a mutation
was present in the donor, the adjusted odds ratio was 0.88 (95% CI, 0.36-2.17; P = .40). When a mutation was pres-
ent in both recipient and donor, the odds ratio was 0.72 (95% CI, 0.22-2.32; P = .29). Among 24 patients with TLR4
mutations in either donor or recipient, 4 (16.7%) developed gram-negative bacteremia. Among 213 patients without
mutations, 14 (6.6%) developed gram-negative bacteremia (P = .09). The data indicate that a reduced risk of acute
GVHD is associated with TLR4 mutations and that TLR4 mutations may increase the risk for gram-negative bac-
teremia. However, these associations are not statistically significant in recipients of HLA-matched sibling marrow
transplants who are prophylactically treated for infections and GVHD. A much larger study population would be
needed to confirm the role of LPS in the pathogenesis of GVHD in humans.
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knockout mouse recapitulates the LPS-hyporesponsive
phenotype [7]. These TLR4-deficient strains are highly
susceptible to gram-negative bacteremia [7,8].
Certain TLR4 alleles in humans have now been associ-
ated with endotoxin hyporesponsiveness [9]. Two cosegre-
gating polymorphisms in the extracellular domain of the
TLR4 receptor were identified in a group of individuals
with LPS-hyporesponsive blood monocytes and blunted air-
way responsiveness to inhaled LPS [10]. Both homozygous
and heterozygous genotypes were associated with LPS
hyporesponsiveness, with heterozygous genotypes having an
intermediate phenotype. Furthermore, these alleles are asso-
ciated with the development of gram-negative sepsis (E.
Lorenz, J.P. Mira, K.L. Frees, D.A. Schwartz, unpublished
data, 2001) and more complications from sepsis in severely
ill patients (R.R. Schumann, E. Lorenz, E. Latz, N. Lim-
mer, P.M. Schlag, D.A. Schwartz, unpublished data, 2001).
The TLR4 Asp299Gly mutation was shown to disrupt
TLR-mediated LPS signaling in vitro more severely than
the TLR4 Thr399Ile mutation. Transfection of the com-
mon wild-type allele of TLR4 rescued the LPS-resistant
phenotype in airway epithelial cells and alveolar macro-
phages from subjects with TLR4 mutations [9].
The objectives of this preliminary study were (1) to deter-
mine the frequency of TLR4 mutations in a large cohort of
HSCT recipients and their HLA-identical donors and (2) to
test the hypothesis that TLR4 mutations in either the recipi-
ent or donor reduce the risk of acute GVHD in allogeneic
HSCT recipients by minimizing the response to LPS.
MATERIALS AND METHODS
Patient Selection 
DNA samples were obtained from a previously
described cohort of patients (n = 237) who received an
HSCT from an HLA-identical sibling [11]. All patients
received methotrexate and cyclosporine for GVHD prophy-
laxis and had either grade 0 or grades II to IV acute GVHD.
Patients with grade I GVHD, patients with renal failure
requiring dialysis, and patients without GVHD who died
before day 80 after transplantation were excluded.
TLR4 Genotyping 
Testing was performed by individuals who did not know
which patients had GVHD. Genotyping was performed
using allele-speciﬁc polymerase chain reaction (PCR) assays
for TLR4 Asp299Gly and TLR4 Thr399Ile mutations. In a
separate study [12] to determine the reliability of the PCR-
based assay, 1 sample each from 10 patients were sequenced
and confirmed the results of the PCR-based restriction-
fragment length–polymorphism assay. The PE Taq poly-
merase kit (PE Applied Biosystems, Foster City, CA) was
employed for PCR reactions. In a total reaction volume of
25 L, 2.5 L of 10× PCR buffer, 20 pmol of each primer
(see below), 0.02 µg of genomic DNA, 5 U of Taq poly-
merase, and 1 L dNTP (deoxyribonucleoside triphos-
phate) mix (Clontech, Palo Alto, CA) were combined.
Primers for TLR4 Asp299Gly were (F5′GATTAGCAT
ACTTAGACTACTACCTCCATG) and (R5′GATCAA
CTTCTGAAAAAGCATTCCCAC). Primers for TLR4
Thr399Ile were (F5 ′GGTTGCTGTTCTCAAAGT
GATTTTGGGAGAA) and (R5′CCT GAAGACTGG
AGAGTGAGTTAAATGCT). The underlined bases in
both forward primers indicate the nucleotide altered to cre-
ate an NcoI (TLR4 Asp299Gly) and a HinfI (TLR4
Thr399Ile) restriction site, respectively. PCR reactions were
run at 95°C for 4 minutes followed by 30 cycles at 95°C for
30 seconds, 55°C for 30 seconds, 72°C for 30 seconds. A
5-µL aliquot of the product was digested with the appropri-
ate restriction enzyme and electrophoresed in a 3%
NuSieve gel to identify the TLR4 alleles.
Statistical Analysis 
GVHD scores were unblinded after all TLR4 typing
was completed. Univariate and multivariate logistic regres-
sion models were used to analyze the association between
risk factors and the probability of acute GVHD. All P values
are 1-sided to match the 1-sided hypothesis that GVHD was
reduced in the mutant allele groups and all P values were
derived from the Wald test. No adjustments were made for
multiple comparisons.
RESULTS AND DISCUSSION
Among 227 donors who were successfully genotyped,
203 had no detected mutations of TLR4 and 24 (10.6%)
had at least 1 TLR4 mutation (Table 1). Among 223 patients
who were genotyped, 199 had no TLR4 mutations detected,
and 24 (10.8%) had at least 1 TLR4 mutation. Of 24 recipi-
ents with TLR4 mutation(s), 14 had donors with TLR4
mutation(s). The allelic frequency for the 299 and 399 poly-
morphisms were 4.7% and 5.3%, respectively, in both the
donor and recipient populations which is in agreement with
the cosegregate nature of the TLR4 mutation. These popu-
lations were in Hardy-Weinberg equilibrium.
Grades II to IV acute GVHD occurred in 94 (47.2%)
of 199 recipients with no TLR4 mutations and in 8 (33.3%)
of 24 recipients with any TLR4 mutations (P = .10) (Table 1).
Acute GVHD occurred in 96 (47.3%) of 203 recipients
whose donors had no TLR4 mutations and in 10 (41.7%)
of 24 recipients whose donors had any TLR4 mutations
(P = .30). From 14 donor-recipient pairs in which both the
donor and recipient had TLR4 mutations, 5 (35.7%)
patients had acute GVHD compared to 89 (49.2%) of the
patients from 181 pairs in which neither the donor nor the
recipient had TLR4 mutations (P = .17). Because of the
small numbers, further analysis according to speciﬁc muta-
tions was not performed. Moreover, LPS hyporesponsive-
ness of varying degrees is expected in both homozygous and
heterozygous individuals [9].
Analysis by logistic regression models gave qualitatively
similar results (Table 2). In this analysis, we also adjusted for
other previously determined risk factors for acute GVHD
including patient age at transplantation, dose of total body
irradiation, and advanced malignancy [11]. The estimated
risks for acute GVHD expressed as an odds ratio was less
than 1.0 when TLR4 mutations were present, but the asso-
ciations were statistically modest.
TLR4 mutations are associated with increased suscepti-
bility to gram-negative bacteremia in mice and patients [8]
(R.R. Schumann, E. Lorenz, E. Latz, N. Limmer, P.M.
Schlag, D.A. Schwartz, unpublished data, 2001). We also
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detected a trend for a similar association in this cohort of
patients, even though they were routinely treated with
antibiotics during neutropenia. In this cohort, 18 patients
had gram-negative bacteremia. Among 24 patients with
TLR4 mutations in either donor or recipient, 4 (16.7%)
developed gram-negative bacteremia. Among 213 patients
without TLR4 mutations, 14 (6.6%) developed bacteremia
(P = .09). The odds ratio was 2.44 (95% CI, 0.87-6.82).
LPS has been postulated to contribute to the pathogen-
esis of GVHD. One paradigm involves translocation of bac-
teria or bacterial products across gut mucosa. LPS may then
prime macrophages for augmented production of effector
molecules (eg, tumor necrosis factor α, nitric oxide) in
response to donor T-cell proinflammatory cytokines. In
murine transplantation models, endotoxemia and macro-
phage activation are associated with GVHD [1]. Transplan-
tation of marrow from donor mice with mutated TLR4
(C3H/HeJ) reduced the severity of GVHD [5]. The biologi-
cal effect of TLR4 mutations observed in murine marrow
transplantation models of GVHD [5] might be obscured in
humans by posttransplantation immunosuppression with
methotrexate and cyclosporine and by antibiotic prophylaxis
during neutropenia. LPS has prominent effects on hemato-
poietic cells, especially those of monocyte-macrophage
lineage. These cells have been considered as important
effectors of LPS-augmented responses in experimental
models of GVHD [1]. Accordingly, we anticipated that pro-
tection from GVHD would come primarily from TLR4
mutations in the donor. Our results suggest that protection
could come from TLR4 mutations in either the donor or
the recipient. Endothelial cells and ﬁbroblasts in the recipi-
ent are responsive to LPS in the presence of soluble CD14
Table 1. Association of TLR4 Mutations and Acute GVHD*
Donor TLR4 Genotype† Acute GVHD Score 
299 399 Grade 0 Grade II Grade III Grade IV
00 00 107 60 33 3
00 01 1
01 00 1
01 01 12 7 2
11 11 1
Patient TLR4 Genotype† Acute GVHD Score
299 399 Grade 0 Grade II Grade III Grade IV
00 00 105 59 32 3
00 01 1
01 00 2
01 01 12 5 2
11 01 1
11 11 1
*Acute GVHD score data are n in each category. TLR indicates toll-like receptor; GVHD, graft-versus-host disease.
†TLR4 genotypes corresponding to Asp299Gly and Thr399Ile as described in text; 0 indicates no mutation; 1, mutation.
Table 2. Logistic Regression Models of TLR4 Mutation as a Risk Factor for Grades II to IV GVHD*
Unadjusted Model Adjusted Model†
TLR4 Genotype‡ Odds Ratio 95% CI P Odds Ratio 95% CI P
Patient
No mutation 1 — — 1 — —
Mutation 0.56 0.23-1.36 .10 0.63 0.25-1.60 .16
Donor
No mutation 1 — — 1 — —
Mutation 0.80 0.34-1.88 .30 0.88 0.36-2.17 .40
Patient and donor§ 
No mutation 1 — — 1
Mutations 0.57 0.19-1.78 .17 0.72 0.22-2.32 .29
*TLR indicates toll-like receptor; GVHD, graft-versus-host disease; CI, conﬁdence interval.
†Adjusted for patient age, dose of total body irradiation, and advanced disease.
‡TLR4 mutations include any mutation as described in the text.
§Analysis included only cases in which donor and recipient had concordant presence or absence of mutations.
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[13] and may contribute to GVHD. Adding to the complex-
ity of genetic susceptibility to GVHD is the recognition that
polymorphic alleles of other TLR family members and
cytokine genes may inﬂuence the recognition of and subse-
quent inﬂammatory response to bacterial products [14,15].
Studies to assess the role of TLR4 and other members
of the toll-like receptor family on GVHD and other impor-
tant end points such as chronic GVHD, infections, and sur-
vival will be limited by the relatively small number of
patients and donors with mutations. This small study popu-
lation limits the power to detect differences that might be
considered to be clinically signiﬁcant, because studies pow-
ered to detect such differences will necessarily be quite
large. For example, if one were to design a cohort study to
assess the association of mutation rate with GVHD based on
the observed data from this study (mutation rate of 10%,
GVHD rate of 50%), 1500 patients would be needed to
achieve 90% power to detect an odds ratio of 0.6 at the
1-sided signiﬁcance of 0.05. Applying more stringent statisti-
cal tests (eg, 2-sided signiﬁcance test) would further increase
the required cohort size and decrease the feasibility of this
approach. Other study designs such as case-control analyses
might be a more productive approach to examining the sus-
ceptibility to GVHD associated with TLR4 alleles and
other genetic polymorphisms in proinﬂammatory pathways.
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